^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SLC9A2 (Solute Carrier Family 9 Member A2)

    i
    Other names: SLC9A2, Solute Carrier Family 9 Member A2, NHE2, Solute Carrier Family 9, Subfamily A (NHE2, Cation Proton Antiporter 2), Member 2, Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Member 2, Sodium/Hydrogen Exchanger 2, Na(+)/H(+) Exchanger 2, Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Isoform 2, Solute Carrier Family 9 Member 2, NHE-2
    9ms
    Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis. (PubMed, J Exp Clin Cancer Res)
    These findings highlight the critical role of SLC9A2 in regulating metastasis, angiogenesis, and TME remodeling in CRC. By modulating the STAT3 pathway and tumor vasculature, SLC9A2 emerges as a potential prognostic biomarker and therapeutic target. Targeting SLC9A2 may enhance immune responses and improve treatment outcomes in CRC, offering a promising avenue for future therapeutic strategies.
    Journal • IO biomarker
    |
    SLC9A2 (Solute Carrier Family 9 Member A2)
    over1year
    Identification and Validation of SLC9A2 as A Potential Tumor Suppressor in Colorectal Cancer: Integrating Bioinformatics Analysis with Experimental Confirmation. (PubMed, Curr Med Sci)
    Our study suggests that SLC9A2 acts as a tumor suppressor through the MAPK pathway and could be a potential target for CRC diagnosis and therapy.
    Journal
    |
    IL17A (Interleukin 17A) • MMP1 (Matrix metallopeptidase 1) • SLC4A4 (Solute carrier family 4 member 4) • SLC9A2 (Solute Carrier Family 9 Member A2) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • MMP7 (Matrix metallopeptidase 7)
    almost2years
    zDHHC3-mediated S-palmitoylation of SLC9A2 regulates apoptosis in kidney clear cell carcinoma. (PubMed, J Cancer Res Clin Oncol)
    Our findings suggest that zDHHC3 plays an important role in KIRC, due partly to its regulation of SLC9A2 S-palmitoylation. The targeting of the zDHHC3-SLC9A2 axis may provide a new option for the clinical treatment of KIRC.
    Journal
    |
    SLC9A2 (Solute Carrier Family 9 Member A2)